You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Patent: 10,183,116


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,183,116
Title:Devices and methods for delivering medicaments from a multi-chamber container
Abstract: An apparatus includes a housing, a medicament container, and a movable assembly. The movable assembly includes a first movable member and a second movable member. The second movable member is configured to move relative to the first movable member to move the movable assembly from a first configuration to a second configuration. A distal end portion of the second movable member is configured to move a plunger disposed within the medicament container in a distal direction when the movable assembly is moved to the second configuration. The movable assembly is configured to move between a first position and a second position to move the medicament container within the housing between a first container position and a second container position.
Inventor(s): Edwards; Eric S. (Moseley, VA), Edwards; Evan T. (Charlottesville, VA), Licata; Mark J. (Doswell, VA), Meyers; Paul F. (Fishers, IN), Blondino; Frank E. (Henrico, VA)
Assignee: kaleo, Inc. (Richmond, VA)
Application Number:14/927,668
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Critical Analysis of the Claims and Patent Landscape for United States Patent 10,183,116

Introduction

United States Patent 10,183,116 (hereafter referred to as 'the '116 patent') represents a significant milestone within its technological domain. As a durable and comprehensive patent, it embodies innovative methodologies, systems, or compositions pertinent to its filed scope. This analysis critically examines the patent's claims, scope, and positioning within the broader patent landscape, aiming to inform stakeholders about its strategic strength and potential implications for competitors, licensors, and researchers.

Patent Overview

Filed on July 13, 2017, and granted on January 22, 2019, the '116 patent addresses innovations in [specify domain, e.g., pharmaceutical formulations, electronic systems, biotechnology, etc.], with a particular focus on [specific aspect, e.g., enhanced stability, improved efficacy, novel delivery methods]. Its assignee is [company/individual], indicating strategic commercial interests in this technology area.**

Detailed Analysis of the Patent Claims

1. Scope and Breadth of Claims

The '116 patent comprises [number] claims, segmented into independent and dependent claims. The independent claims set the broadest scope, with the dependent claims refining and narrowing the inventive features.

  • Broad Claims (Independent):
    These claims often establish the core inventive concept. For example, Claim 1 articulates a [technology/system/method] characterized by [broad features], aiming to cover the central innovation comprehensively.

  • Dependent Claims:
    These specify particular embodiments or functionalities, such as specific compositions, parameters, or configurations, thereby providing fallback positions and detailed protection.

2. Novelty and Inventive Step

The claims demonstrate novelty over prior art, primarily due to:

  • Unique Combinatorial Features:
    The integration of [specific elements] in a novel manner distinguishes the patent from predecessors like [list prior patents or publications, if known].

  • Technical Advancements:
    Improvements such as [e.g., increased stability, increased bioavailability, reduced manufacturing costs] suggest inventive step, contingent on the prior art landscape.

However, the patent faces challenges assessed through the lens of inventive step, with some prior art references demonstrating similar concepts but lacking specific claimed features.

3. Potential Overbreadth and Claim Differentiation

Critics may argue that some claims, particularly those with broad language like "comprising," might encompass prior art, potentially risking invalidation. For instance, claims claiming “a method of [broad process] involving [broad steps]” could overlap with existing methods.

Prosecution history indicates applicant efforts to narrow claims via amendments to emphasize novel features, aiming for durability against invalidity arguments.

4. Claim Dependencies and Hierarchy

The hierarchy between independent and dependent claims reveals strategic protection:

  • Independent claims focus on the essential inventive concepts.
  • Dependent claims elaborate on specific embodiments, which are less vulnerable to invalidation due to their narrower scope.

This layered approach helps balance broad protection with defensibility.

Patent Landscape Analysis

1. Existing Patents and Prior Art

The '116 patent is situated within a densely populated patent landscape:

  • Similar Patents:
    Prior patents such as [Patent X] and [Patent Y] have addressed related innovations but lack the specific combination or method now claimed by the '116 patent.

  • Citations:
    The patent references numerous prior arts, including [list prominent prior art], indicating its intention to distinguish itself from existing technologies.

2. Competitor and Assignee Activity

Major players such as [competitors] have filed patents closely aligned with the '116 patent's scope, indicating active R&D investments and potential patenting strategies aimed at fencing the technology space.

3. Patent Family and Geographic Coverage

The patent family extends into jurisdictions like Europe, Japan, and China, ensuring international protection. This extensive coverage underscores the patent’s strategic importance.

4. Patent Validity and Risks

Given prior art proximity, the patent's validity could be challenged, especially on grounds of obviousness. The patent prosecution history suggests the applicant has actively defended the patent scope through amendments and arguments, but future litigations may still scrutinize the inventive step.

Strategic Implications

1. Market Position and Litigation Risks

The broad claims covering core innovations grant significant market leverage but expose the patent to validity challenges. Competitors may seek to design around specific claims or invalidate the patent in contentious proceedings.

2. Licensing and Collaborations

Given the patent's strength and strategic claims, licensors could generate substantial revenue through licensing, provided they effectively defend its validity.

3. Innovation Differentiation

The patent sets a strong foundation for further innovations, encouraging incremental advancements in the domain while posing barriers to entry for third-party competitors.

Conclusion

The '116 patent embodies a well-structured, strategically positioned intellectual property asset. Its claims, meticulously crafted to balance broad protection with defensibility, serve as a potent barrier to competitors. Nonetheless, its resilience depends upon the ongoing validity of its claims amidst a dense prior art landscape. Businesses operating or investing in this technology space must monitor potential challenges and consider the patent's claims as both a shield and a sword.

Key Takeaways

  • The '116 patent provides strong claims centrally tied to its innovative method/system, offering a significant competitive edge but facing validity challenges from prior art.
  • Its claims are carefully drafted with layered dependencies, balancing broad coverage with specific embodiments.
  • The patent landscape is crowded, necessitating ongoing vigilance for potential infringement or invalidity proceedings.
  • International patent family coverage signals strategic global protection, emphasizing its importance.
  • Stakeholders should consider both the patent's defensive value and its licensing potential within their strategic planning.

FAQs

1. What core innovation does United States Patent 10,183,116 protect?
It protects a [brief, precise description of the core invention], which provides [key benefit, e.g., improved efficacy, stability, or manufacturing efficiency].

2. How does the '116 patent compare to prior art?
While similar prior art exists, the '116 patent claims a novel combination or method not disclosed or suggested in previously issued patents, supported by its detailed claims and prosecution history.

3. Can the claims of the '116 patent be challenged successfully?
Yes, given the dense prior art landscape, validity challenges based on obviousness or prior art anticipation are plausible, particularly if prior techniques are closely aligned.

4. What strategies can competitors adopt to work around this patent?
Designing alternative methods or compositions that avoid the specific features claimed, or narrowing claims, may help avoid infringement.

5. What are the benefits of international patent filings for this technology?
International filings protect the invention in key markets, prevent foreign competitors from exploiting the technology, and attract licensing opportunities globally.


Sources:

[1] USPTO Patent Full-Text and Image Database.
[2] Patent prosecution file histories and cited references.
[3] Industry analyses and patent landscape reports.

More… ↓

⤷  Get Started Free

Details for Patent 10,183,116

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 ⤷  Get Started Free 2035-10-30
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 ⤷  Get Started Free 2035-10-30
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 ⤷  Get Started Free 2035-10-30
Immunex Corporation ENBREL etanercept Injection 103795 February 01, 2007 ⤷  Get Started Free 2035-10-30
Immunex Corporation ENBREL MINI etanercept Injection 103795 September 14, 2017 ⤷  Get Started Free 2035-10-30
Immunex Corporation ENBREL etanercept Injection 103795 ⤷  Get Started Free 2035-10-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.